Mark G. Kris MD – MSK Thoracic Medical Oncologist is a dedicated oncologist located in New York, New York, specializing in the treatment of lung cancers. Based in the 10021 postal area, this practice focuses on providing expert medical care for individuals diagnosed with thoracic malignancies, particularly those originating in the lungs. The approach integrates advanced diagnostic and therapeutic strategies tailored to each patient’s unique genetic tumor profile. Patients can reach the office by phone at 347-798-9489 for consultations and appointments.
This oncologist combines clinical expertise with ongoing research to improve treatment outcomes for lung cancer patients. The research efforts concentrate on identifying genetic alterations within cancer cells that may serve as targets for new, more effective therapies. By leading a team that studies the molecular characteristics of tumors, the practice aims to develop and evaluate anticancer drugs designed to attack lung cancers at their genetic roots. This research-driven approach informs personalized treatment plans that extend beyond conventional methods.
Collaboration plays a key role in the care model at Mark G. Kris MD – MSK Thoracic Medical Oncologist. The practice works closely with thoracic surgeons and radiation oncologists to create comprehensive treatment regimens. This multidisciplinary coordination seeks to optimize the use of surgery, radiotherapy, and pharmacologic therapies to enhance the potential for curative outcomes. The integration of these modalities reflects a commitment to evidence-based care that addresses the complexity of lung cancer management.
Situated in a leading medical hub, this oncologist provides specialized care that reflects the latest advancements in thoracic oncology. The emphasis on genetic research and collaborative treatment planning offers patients access to innovative approaches within a supportive clinical setting. Mark G. Kris MD – MSK Thoracic Medical Oncologist remains focused on advancing the understanding and treatment of lung cancers to improve patient prognosis and quality of life.
